MedTrace Logo

Stem Cells Therapy for Corneal Blindness

NCT02948023 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2018-03-06

No results posted yet for this study

Summary

This is a investigative initiated, comparative pilot clinical trial to ascertain the safety of application of ex-vivo cultivated limbal stem cells in human eyes for treating different superficial corneal pathologies. Pre-clinical work in murine models have already demonstrated efficacy of this technique in curing murine corneal pathologies.

Conditions

  • Corneal Injuries
  • Corneal Burns
  • Corneal Scars and Opacities

Interventions

BIOLOGICAL

Ex-vivo cultivated limbal stem cell pool

0.5 million stromal and epithelial cells will be incorporated in 0.05ml of commercially available fibrin glue and pasted over the corneal lesion after epithelial debridement.

Sponsors & Collaborators

  • L.V. Prasad Eye Institute

    lead OTHER

Principal Investigators

  • Sayan Basu, MBBS, MS · LV Prasad Eye Institiute

  • Vivek Singh, MSc PhD · LV Prasad Eye Institiute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2019-02-28
Completion
2019-08-31

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02948023 on ClinicalTrials.gov